How should hyperbilirubinemia be evaluated and treated?

Evaluation and Treatment of Hyperbilirubinemia

Initial Evaluation: Distinguish Neonatal from Adult Hyperbilirubinemia

The evaluation and treatment of hyperbilirubinemia fundamentally differs between neonates (≥35 weeks gestation) and older children/adults, with neonatal hyperbilirubinemia requiring urgent phototherapy based on hour-specific nomograms while adult hyperbilirubinemia demands investigation of the conjugated versus unconjugated fraction to identify underlying hepatobiliary disease or hemolysis. 1

---

NEONATAL HYPERBILIRUBINEMIA (≥35 Weeks Gestation)

Diagnostic Approach

• Measure total serum bilirubin (TSB) as the definitive diagnostic test to guide all interventions 1
• Obtain TSB if transcutaneous bilirubin (TcB) is within 3.0 mg/dL of phototherapy threshold, exceeds the threshold, or is ≥15 mg/dL 1
• Calculate rate of rise when multiple measurements available: rapid rise (≥0.3 mg/dL/hour in first 24 hours or ≥0.2 mg/dL/hour thereafter) suggests hemolysis 1
• Evaluate for underlying causes in any infant requiring phototherapy, including glucose-6-phosphate dehydrogenase (G6PD) deficiency testing if TSB rises despite intensive phototherapy or rises after initial decline 1

Risk Stratification

Key risk factors for severe hyperbilirubinemia: 2

• Younger gestational age (35-37 weeks)
• Exclusive breastfeeding with inadequate caloric intake
• Positive direct antiglobulin test (DAT)
• Hemolytic disease

Treatment Thresholds

Initiate intensive phototherapy based on: 1

• Gestational age
• Presence of neurotoxicity risk factors
• Infant age in hours (use hour-specific nomograms)

The 2022 AAP guidelines raised phototherapy thresholds compared to 2004 guidelines, safely reducing unnecessary treatment without increasing kernicterus risk 3, 4, 5, 6

Phototherapy Implementation

"Crash-cart" approach for TSB >25 mg/dL: 1

• Implement phototherapy immediately to reduce exchange transfusion need and minimize bilirubin neurotoxicity
• Maximize body surface area exposure to light source
• Verify efficacy by measuring TSB after initiation, with timing guided by TSB trajectory and infant age 1

Discontinuation criteria: 1

• Stop when TSB declines 2-4 mg/dL below the hour-specific threshold at initiation
• Consider TSB level at phototherapy start, underlying cause, and rebound risk

Post-Treatment Monitoring

High-risk infants require follow-up TSB 8-12 hours after discontinuation and the following day if: 1

• Phototherapy received <48 hours of age
• Gestational age <38 weeks
• Positive DAT or suspected hemolytic disease

Home Phototherapy Option

For discharged infants with TSB above threshold: home LED-based phototherapy is an alternative to readmission for infants meeting specific criteria (well-appearing, no hemolysis, reliable follow-up) 1

Breastfeeding Management

Critical pitfall: Do not interrupt breastfeeding for jaundice treatment, as this increases early discontinuation risk 2

• Encourage frequent feeding to maintain adequate caloric intake
• Provide professional support to promote continued breastfeeding during phototherapy 2

---

ADULT/OLDER CHILD HYPERBILIRUBINEMIA

Diagnostic Algorithm

Step 1: Fractionate the bilirubin 1

• Measure conjugated and unconjugated fractions
• Most measurable bilirubin should be conjugated, even in significant liver disease

Step 2: Interpret based on predominant fraction

Unconjugated Hyperbilirubinemia (in absence of hemolysis)

Gilbert's syndrome is virtually always the cause 1

• Inherited disorder with reduced glucuronyltransferase activity
• Most common cause of isolated elevated bilirubin
• Patients require complete reassurance; no treatment needed 1
• Exclude hemolysis through complete blood count, reticulocyte count, peripheral smear, lactate dehydrogenase, and haptoglobin

Conjugated Hyperbilirubinemia

Indicates parenchymal liver disease or biliary obstruction 1

• Check alkaline phosphatase (ALP) and γ-glutamyltransferase (GGT)
• Elevated ALP with elevated GGT confirms hepatic origin 1
• Proceed with comprehensive hepatobiliary evaluation including imaging (ultrasound, CT, or MRI)
• Assess synthetic function: albumin, prothrombin time/INR (prolongation indicates >70% loss of synthetic function) 1

Special Populations

Neonates and infants with conjugated bilirubin >25 μmol/L: 1

• Require urgent referral to pediatrician for possible liver disease assessment
• This is NOT physiologic jaundice

Physiologic neonatal jaundice: 1

• Unconjugated hyperbilirubinemia in first weeks of life
• Pathological if high or prolonged

---

Key Clinical Pitfalls

• Do not rely solely on visual assessment of jaundice; always obtain objective bilirubin measurement 1, 2
• Do not overinterpret albumin as liver disease severity marker; it decreases in sepsis, inflammation, nephrotic syndrome, and malabsorption 1
• Avoid unnecessary phototherapy by using updated 2022 thresholds, which have reduced treatment rates without adverse outcomes 5, 6
• Recent evidence shows implementation of 2022 AAP guidelines decreased serum bilirubin testing from 21.3% to 8.8% and phototherapy from 4.2% to 1.4% without increasing readmissions or kernicterus 5